Particle Works has published an Application Note discussing the development of nanoparticles as drug carriers for specific action sites.
The company offers solutions underpinned by microfluidics and automation for the sometimes complex and challenging synthesis of nanoparticles for drug delivery, enabling researchers to accelerate their nanomedicine development.
The Automated Nanoparticle (ANP) System provides automated process optimisation and continuous manufacturing capabilities in a single system which enables researchers to automatically optimise process parameters and generate test samples. Whilst the company’s ALiS System is suitable for screening low volumes of various formulations in a 96-wellplate format, the ANP System can be used to optimise the size, shape, and structure of nanoparticles ahead of final production/commercialisation.
It can be used in ‘protocol mode’ for executing a table of automated and low-volume experiments from a fixed pair of injected reagents. Using the Flow Control Centre (FCC) software, users can optimise the flow rate ratio (FRR), total flow rate (TFR), NP precursor volume, sample collection volume and allow optional in-line dilution. Once a desired set of experimental conditions have been identified, the user can then switch to ‘ontinuous mode’ to create litres of nanoparticles for pre-clinical trials and extensive characterisation. The ANP System bridges the gap between formulation screening and commercial scale manufacturing in a single system solution.
To learn more about nanoparticle synthesis solutions and the capabilities of the ANP System, download the Application Note.
